Frontlight ResearchEarly access
Taking people in NetherlandsPhase 4
Tests mepolizumab in adults with eosinophilic granulomatosis with polyangiitis
Studies how mepolizumab affects nasal bacteria and immune response in eosinophilic granulomatosis with polyangiitis.
Key facts
- Who runs it
- Universitair Medisch Centrum Groningen
- Where
- Groningen, NetherlandsSee the site
- Trial code
- Registry title
- eGPA and local inflammation within the ENT area
- Status
- Recruiting
- Phase
- Phase 4
- People taking part
- 150 people, planned
- Started
- 13 Feb 2024
- Expected to end
- 1 Dec 2027
- Type of study
- Interventional
- Record updated
- 2 February 2024
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with eGPA, and also adults with GPA, severe asthma or nasal polyps, and healthy controls.
- Age
- Older than 18 years.
- Sex
- All sexes can join.
- Disease stage
- Each group has its own disease requirement. eGPA group: meets the 2022 ACR/EULAR criteria for eGPA. GPA group: meets the ACR/EULAR GPA criteria. Nasal polyp group: polyps on both sides of the nose seen by endoscopy or CT scan. Severe asthma group: clinical asthma with FEV1 below 80% and either reversibility of more than 12% or a positive metacholine challenge (PC20 below 8 mg/ml). Healthy group: no asthma symptoms and no bronchial hyperresponsiveness.
- Earlier treatment
- Healthy controls cannot have used immunosuppressive medication or local anti-inflammatory agents long-term, or antibiotics in the last month. Nobody can have used dupilumab within 6 months before the baseline visit. Nasal polyp group: no current asthma medication.
Main reasons for not taking part
- Cannot give informed consent
- Active smoking less than 6 months before the baseline visit
- Pregnant or breastfeeding women
- Use of dupilumab within 6 months of the baseline visit
- Nasal polyp group: current use of asthma medication, or eGPA
The registry criteria, word for word
Show all 15 criteriaShow less
Who can take part
- >18 years of age
- Able to give informed consent
- In CRSwNP group: availability of bilateral nasal polyps as diagnosed by endoscopy or CT scan
- In Severe asthma group: clinical diagnosis of asthma with FEV1 <80% AND either FEV1 reversibility >12% initial or documented positive metacholine challenge (PC20 < 8 mg/ml)
- In eGPA group: Fulfilling the 2022 ACR/EULAR criteria for eGPA (Wechsler et al., 2017)
- In GPA group: fulfilling the ACR/EULAR GPA criteria (Robson et al., 2022)
- In healthy controls: absence of asthma symptoms, no bronchial hyperresponsiveness
Who cannot take part
- In CRSwNP group: current use of asthma medication, eGPA
- In healthy controls: use of immunosuppressive medication
- concomitant use of dupilumab within 6 months of baseline visit
- Unable to give informed consent
- Active smoking < (less than) 6 months from baseline visit
- Pregnant or breastfeeding woman
- In healthy controls: chronic use of local anti-inflammtory agents
- In healthy controls: use of antibiotics within the last month (before start study/screening/)
Where in Netherlands
- Universitair Medisch Centrum GroningenGroningen, NetherlandsTaking people
About the trial
What the trial wants to find out
In eGPA patients treatment with mepolizumab restores changes of the nasal microbiome healthy control phenotype
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorData and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).
- Official title
- eGPA and local inflammation within the ENT area; Impact of Mepolizumab treatment on the nasal microbiome and local and systemic immune response in eosinophilic granulomatosis with polyangitis (eGPA)
- Plain-language title
- Tests mepolizumab in adults with eosinophilic granulomatosis with polyangiitisGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 9 November 2026.
- Record updated
- 2 February 2024